Compare TACT & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TACT | IXHL |
|---|---|---|
| Founded | 1996 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.1M | 49.1M |
| IPO Year | 1996 | N/A |
| Metric | TACT | IXHL |
|---|---|---|
| Price | $4.47 | $0.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 49.1K | ★ 10.4M |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,258,000.00 | $12,000.00 |
| Revenue This Year | $21.67 | $1,188.37 |
| Revenue Next Year | $7.63 | $3,569.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.27 | N/A |
| 52 Week Low | $3.12 | $0.08 |
| 52 Week High | $5.70 | $2.25 |
| Indicator | TACT | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 57.52 |
| Support Level | $4.30 | $0.35 |
| Resistance Level | $4.75 | $0.37 |
| Average True Range (ATR) | 0.25 | 0.02 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 64.71 | 96.49 |
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.